UPDATE: Bio-Quant Launches GPCR-Screening Division | GenomeWeb

NEW YORK, Sept. 5 - Bio-Quant has created a new business division designed to offer screening technology for G protein-coupled receptors, the company said on Wednesday. 

GPCRs function as the delivery mechanism for more than 50 percent of all drugs currently on the market. To facilitate the discovery of additional GPCRs that might serve as drug targets, Bio-Quant’s new business unit will provide platforms that screen for cell motility and GPCR activation. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.